Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer

References

• GLOBOCAN estimated cancer incidence, mortality, and prevalence worldwide in 2018. 2018 [accessed 2022 Dec]. Available from: http://globocan.iarc.fr
   Google Scholar
• Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24(5):487–491.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat E, et al. EAU Guideline Non-muscle-invasive Bladder Cancer. Presented at the EAU Annual Congress Amsterdam. 2020. http://uroweb.org/guidelines/compilations-of-all-guidelines/
   Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in Non-Muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1–11.
   PubMed Web of Science ®Google Scholar
• Aziz A, May M, Burger M, PROMETRICS 2011 research group, et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective european multicenter cohort. Eur Urol. 2014;66(1):156–163.
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Mallin K, Weaver MA, et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the national cancer data base. BJU Int. 2014;114(1):46–55.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–994; quiz 1235.
   PubMed Web of Science ®Google Scholar
• Parker WP, Smelser W, Lee EK, et al. Utilization and outcomes of radical cystectomy for high-grade non-muscle-invasive bladder cancer in elderly patients. Clin Genitourin Cancer. 2017; S1558-7673(17)30208-2.
   Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized High-Risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483–492.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Verhaegh G, Jansen CF, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173(4):1375–1380.
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2017;34:988–993.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC, Franckena M, Ten Hagen TLM. A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy. Adv Drug Deliv Rev. 2020;163-164:145–156.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411–1417.
   PubMed Web of Science ®Google Scholar
• van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351–362.
   PubMed Web of Science ®Google Scholar
• Liem EI, Crezee H, de la Rosette JJ, et al. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia. 2016;32(4):363–373.
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270–4276.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk Non-Muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63–71.
   PubMed Web of Science ®Google Scholar
• Brummelhuis ISG, Wimper Y, Witjes-van Os H, et al. Long-Term experience with Radiofrequency-Induced hyperthermia combined with intravesical chemotherapy for Non-Muscle invasive bladder cancer. Cancers (Basel). 2021;13(3):377.
   PubMed Web of Science ®Google Scholar
• Franckena M, Fatehi D, de Bruijne M, et al. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer. 2009;45(11):1969–1978.
   PubMed Web of Science ®Google Scholar
• Refaat T, Sachdev S, Sathiaseelan V, et al. Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. Breast. 2015;24(4):418–425.
   PubMed Web of Science ®Google Scholar
• Kroesen M, Mulder HT, van Holthe JML, et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiother Oncol. 2019;140:150–158.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
   PubMed Web of Science ®Google Scholar
• Bakker A, van der Zee J, van Tienhoven G, et al. Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: a systematic review. Int J Hyperthermia. 2019;36(1):1024–1039.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20(14):3156–3164.
   PubMed Web of Science ®Google Scholar
• Schaaf L, van der Kuip H, Zopf W, et al. A temperature of 40 °C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC. Ann Surg Oncol. 2015;22 Suppl 3: s758–s765.
   PubMed Web of Science ®Google Scholar
• Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and. (Accessed 6th of September)
   Google Scholar
• Datum van overlijden van personen die ingeschreven staan in de GBA. Available at: https://www.cbs.nl/.
   Google Scholar
• Ohguri T, Harima Y, Imada H, et al. Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial. Int J Hyperthermia. 2018;34(4):461–468.
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, Witjes JA, Aklan B, et al. Inducing intravesical hyperthermia of the ex-vivo porcine bladder wall: radiofrequency-induction versus recirculation using a custom-made device. Int J Hyperthermia. 2018;35(1):323–329.
   PubMed Web of Science ®Google Scholar
• Datta NR, Marder D, Datta S, et al. Quantification of thermal dose in moderate clinical hyperthermia with radiotherapy: a relook using temperature-time area under the curve (AUC). Int J Hyperthermia. 2021;38(1):296–307.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Viglianti BL, Lora-Michiels M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia. 2003;19(3):267–294.
   PubMed Web of Science ®Google Scholar
• Field SB, Morris CC. The relationship between heating time and temperature: its relevance to clinical hyperthermia. Radiother Oncol. 1983;1(2):179–186.
   PubMedGoogle Scholar
• Issels R, Kampmann E, Kanaar R, et al. Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application. Int J Hyperthermia. 2016;32(1):89–95.
   PubMed Web of Science ®Google Scholar
• Bakker A, Tello Valverde CP, van Tienhoven G, et al. Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: temperature matters. Radiother Oncol. 2022;167:149–157.
   PubMed Web of Science ®Google Scholar
• Nakahara S, Ohguri T, Kakinouchi S, et al. Intensity-Modulated radiotherapy with regional hyperthermia for High-Risk localized prostate carcinoma. Cancers (Basel). 2022;14(2):400.
   PubMed Web of Science ®Google Scholar
• de Bruijne M, van der Holt B, van Rhoon GC, et al. Evaluation of CEM43 degrees CT90 thermal dose in superficial hyperthermia: a retrospective analysis. Strahlenther Onkol. 2010;186(8):436–443.
   PubMed Web of Science ®Google Scholar
• Oldenborg S, Griesdoorn V, van Os R, et al. Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: size matters. Radiother Oncol. 2015;117(2):223–228.
   PubMed Web of Science ®Google Scholar
• Linthorst M, Baaijens M, Wiggenraad R, et al. Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: results in 248 patients. Radiother Oncol. 2015;117(2):217–222.
   PubMed Web of Science ®Google Scholar
• Stahl R, Wang T, Lindner LH, et al. Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). Int J Hyperthermia. 2009;25(4):289–298.
   PubMed Web of Science ®Google Scholar
• Issels RD, Prenninger SW, Nagele A, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol. 1990;8(11):1818–1829.
   PubMed Web of Science ®Google Scholar
• Geijsen ED, de Reijke TM, Koning CC, et al. Combining mitomycin C and regional 70 MHz hyperthermia in patients with nonmuscle invasive bladder cancer: a pilot study. J Urol. 2015;194(5):1202–1208.
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, et al. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2014;30(3):171–175.
   PubMed Web of Science ®Google Scholar
• Fatehi D, van der Zee J, Notenboom A, et al. Comparison of intratumor and intraluminal temperatures during locoregional deep hyperthermia of pelvic tumors. Strahlenther Onkol. 2007;183(9):479–486.
   PubMed Web of Science ®Google Scholar
• Juang T, Stauffer PR, Craciunescu OA, et al. Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30(3):176–183.
   PubMed Web of Science ®Google Scholar
• Tan WS, Prendergast A, Ackerman C, et al. Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol. 2022; S0302-2838(22)02552-0.
   Web of Science ®Google Scholar
• Stauffer PR, van Rhoon GC. Overview of bladder heating technology: matching capabilities with clinical requirements. Int J Hyperthermia. 2016;32(4):407–416.
   PubMed Web of Science ®Google Scholar
• Gonzalez EJ, Merrill L, Vizzard MA. Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function. Am J Physiol Regul Integr Comp Physiol. 2014;306(12):R869–878.
   PubMed Web of Science ®Google Scholar